Background: Hepatic fibrosis is an inflammatory liver disease, and there is no effective therapy at present. Astilbin is a bioactive ingredient found in many medicinal and food plants, with antioxidative, anti-inflammatory, and antitumor properties. Objectives: This study aimed to investigate the protective effect and related molecular mechanism of astilbin against carbon tetrachloride (CCl4)-induced liver fibrosis in rats. Methods: Liver fibrosis was induced by injection of CCl4 in male Sprague-Dawley rats, and those rats were then treated with astilbin at different concentrations. Pathological changes, collagen production, inflammatory cytokine, and oxidative stress were evaluated to evaluate the effects of astilbin on CCl4-induced hepatic fibrosis. Real-time PCR and western blot were performed to detect the mRNA and protein expression of indicated genes. Results: We discovered that CCl4 caused significant fibrosis damage in rat liver, and astilbin dose-dependently improved the liver functions and fibrosis degree. Astilbin treatment significantly decreased collagen production, inflammatory response, and oxidative stress in vivo. Mechanically, administration of astilbin obviously elevated the hepatic levels of Nrf2 and its downstream components, including NAD(P)H:quinone oxidoreductase 1 (Nqo1), heme oxygenase (HO-1), glutamate-cysteine ligase catalytic subunit, and glutamate cysteine ligase modifier. Conclusions: Taken together, these findings demonstrate that astilbin could protect against CCL4 induced-liver fibrosis in rats.

1.
Xu
F
,
Liu
C
,
Zhou
D
,
Zhang
L
.
TGF-β/SMAD pathway and its regulation in hepatic fibrosis
.
J Histochem Cytochem
.
2016 Mar
;
64
(
3
):
157
67
. .
2.
Yanny
B
,
Winters
A
,
Boutros
S
,
Saab
S
.
Hepatic encephalopathy challenges, burden, and diagnostic and therapeutic approach
.
Clin Liver Dis
.
2019 Nov
;
23
(
4
):
607
23
. .
3.
Shackel
NA
,
Vadas
MA
,
Gamble
JR
,
McCaughan
GW
.
Beyond liver fibrosis: hepatic stellate cell senescence links obesity to liver cancer by way of the microbiome
.
Hepatology
.
2014 Jun
;
59
(
6
):
2413
5
. .
4.
Yan
L
,
Lu
LG
.
Department of Gastroenterology, Shanghai General Hospital,Shanghai Jiao Tong University School of Medicine. Molecular basis of hepatic fibrosis and current status of its diagnosis and treatment
.
J Clin Hepatol
.
2018
.
5.
Cai
Y
,
Chen
T
,
Xu
Q
.
Astilbin suppresses collagen-induced arthritis via the dysfunction of lymphocytes
.
Inflamm Res
.
2003 Aug
;
52
(
8
):
334
40
. .
6.
Xu
Q
,
Wu
F
,
Cao
J
,
Chen
T
,
Jiang
J
,
Saiki
I
, et al.
Astilbin selectively induces dysfunction of liver-infiltrating cells--novel protection from liver damage
.
Eur J Pharmacol
.
1999 Jul
;
377
(
1
):
93
100
. .
7.
Fei
M
,
Wu
X
,
Xu
Q
.
Astilbin inhibits contact hypersensitivity through negative cytokine regulation distinct from cyclosporin A
.
J Allergy Clin Immunol
.
2005 Dec
;
116
(
6
):
1350
6
. .
8.
Wang
J
,
Zhao
Y
,
Xu
Q
.
Astilbin prevents concanavalin A-induced liver injury by reducing TNF-α production and T lymphocyte adhesion
.
J Pharm Pharmacol
.
2004 Apr
;
56
(
4
):
495
502
. .
9.
Zhang
CY
,
Zhu
JY
,
Ye
Y
,
Zhang
M
,
Zhang
LJ
,
Wang
SJ
, et al.
Erhuang Formula ameliorates renal damage in adenine-induced chronic renal failure rats via inhibiting inflammatory and fibrotic responses
.
Biomed Pharmacother
.
2017 Nov
;
95
:
520
8
. .
10.
Zhang
J
,
Liu
H
,
Song
C
,
Zhang
J
,
Wang
Y
,
Lv
C
, et al.
Astilbin ameliorates pulmonary fibrosis via blockade of Hedgehog signaling pathway
.
Pulm Pharmacol Ther
.
2018 Jun
;
50
:
19
27
. .
11.
Yang
Y
,
Chen
XX
,
Li
WX
,
Wu
XQ
,
Huang
C
,
Xie
J
, et al.
EZH2-mediated repression of Dkk1 promotes hepatic stellate cell activation and hepatic fibrosis
.
J Cell Mol Med
.
2017 Oct
;
21
(
10
):
2317
28
. .
12.
Krenkel
O
,
Puengel
T
,
Govaere
O
,
Abdallah
AT
,
Mossanen
JC
,
Kohlhepp
M
, et al.
Therapeutic inhibition of inflammatory monocyte recruitment reduces steatohepatitis and liver fibrosis
.
Hepatology
.
2018 Apr
;
67
(
4
):
1270
83
. .
13.
Lu
G
,
Zhang
J
,
Liu
X
,
Liu
W
,
Cao
G
,
Lv
C
, et al.
Regulatory network of two circRNAs and an miRNA with their targeted genes under astilbin treatment in pulmonary fibrosis
.
J Cell Mol Med
.
2019 Oct
;
23
(
10
):
6720
9
. .
14.
Wang
SW
,
Xu
Y
,
Weng
YY
,
Fan
XY
,
Bai
YF
,
Zheng
XY
, et al.
Astilbin ameliorates cisplatin-induced nephrotoxicity through reducing oxidative stress and inflammation
.
Food Chem Toxicol
.
2018 Apr
;
114
:
227
36
. .
15.
Wang
M
,
Zhao
J
,
Zhang
N
,
Chen
J
.
Astilbin improves potassium oxonate-induced hyperuricemia and kidney injury through regulating oxidative stress and inflammation response in mice
.
Biomed Pharmacother
.
2016 Oct
;
83
:
975
88
. .
16.
Kong
G
,
Huang
X
,
Wang
L
,
Li
Y
,
Sun
T
,
Han
S
, et al.
Astilbin alleviates LPS-induced ARDS by suppressing MAPK signaling pathway and protecting pulmonary endothelial glycocalyx
.
Int Immunopharmacol
.
2016 Jul
;
36
:
51
8
. .
17.
Espino
J
,
Rodríguez
AB1
,
Pariente
JA
.
Melatonin and oxidative stress in the diabetic state: clinical implications and potential therapeutic applications
.
Curr Med Chem
.
2019
;
26
(
22
):
4178
90
.
18.
Ndisang
JF
.
Synergistic interaction between heme oxygenase (HO) and nuclear-factor E2- related factor-2 (Nrf2) against oxidative stress in cardiovascular related diseases
.
Curr Pharm Des
.
2017
;
23
(
10
):
1465
70
. .
19.
Mizunoe
Y
,
Kobayashi
M
,
Sudo
Y
,
Watanabe
S
,
Yasukawa
H
,
Natori
D
, et al.
Trehalose protects against oxidative stress by regulating the Keap1-Nrf2 and autophagy pathways
.
Redox Biol
.
2018 May
;
15
(
C
):
115
24
. .
20.
Kang
KA
,
Hyun
JW
.
Oxidative stress, Nrf2, and epigenetic modification contribute to anticancer drug resistance
.
Toxicol Res
.
2017 Jan
;
33
(
1
):
1
5
. .
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.